Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors

Mol Pharm. 2020 Aug 3;17(8):2849-2863. doi: 10.1021/acs.molpharmaceut.0c00247. Epub 2020 Jul 22.

Abstract

In pancreatic ductal adenocarcinoma (PDAC), early onset of hypoxia triggers remodeling of the extracellular matrix, epithelial-to-mesenchymal transition, increased cell survival, the formation of cancer stem cells, and drug resistance. Hypoxia in PDAC is also associated with the development of collagen-rich, fibrous extracellular stroma (desmoplasia), resulting in severely impaired drug penetration. To overcome these daunting challenges, we created polymer nanoparticles (polymersomes) that target and penetrate pancreatic tumors, reach the hypoxic niches, undergo rapid structural destabilization, and release the encapsulated drugs. In vitro studies indicated a high cellular uptake of the polymersomes and increased cytotoxicity of the drugs under hypoxia compared to unencapsulated drugs. The polymersomes decreased tumor growth by nearly 250% and significantly increased necrosis within the tumors by 60% in mice compared to untreated controls. We anticipate that these polymer nanoparticles possess a considerable translational potential for delivering drugs to solid hypoxic tumors.

Keywords: hypoxia-responsive; nanoparticles; pancreatic cancer; polymersomes; tumor-penetrating.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology*
  • Carcinoma, Pancreatic Ductal / drug therapy
  • Cell Line, Tumor
  • Female
  • Humans
  • Hypoxia / drug therapy*
  • Male
  • Mice
  • Mice, Nude
  • Nanoparticles / chemistry*
  • Neoplastic Stem Cells / drug effects
  • Pancreatic Neoplasms / drug therapy*
  • Polymers / chemistry

Substances

  • Antineoplastic Agents
  • Polymers